Worries About 180-Day Exclusivity Reforms Persist As User Fee Bill Advances
Generic advocates worry FDA's model legislation might render the 180-day exclusivity incentive almost irrelevant. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images 
